Zhitong Financial APP learned that Soochow Securities released a research report sayingLooking at the synthetic biology company from the three dimensions of research and development, selection and scale-up production, the company has an integrated R & D platform and a selection strategy with rich market application scenarios and synergy among products downstream of the selected varieties. companies with perfect technology to scale up production capacity are the benchmark of the industry. From the point of view of the global platform synthetic biology leading company Ginkgo Bioworks, platform synthetic biology enterprises are active in epitaxial mergers and acquisitions in order to improve the platform capability and form a closed loop of business capability.
In terms of investment opportunities, it is recommended to focus on the companies providing upstream low-level technical services under the tuyere of synthetic biology: Genscript Biotech Corporation (gene synthesis field), Bai Oseatu (02315) (gene editing field), 688114.SH (gene sequencing field) Focus on the platform and product line synthetic biology companies that are competitive in R & D, selection and scale-up production: 688065.SH, 688639.SH, 688363.SH and 301301.SZ.
The main points of ▍ Soochow Securities are as follows:
Through the targeted design, transformation and even re-synthesis of organisms, synthetic biology can realize a new manufacturing method of material processing and synthesis by using synthetic organisms as tools.
Benefiting from the great progress in the fields of gene synthesis and editing, synthetic biology has gradually developed into a research and development mode with "design-build-test-learning" (DBTL cycle) as the core and a large-scale production mode dominated by fermentation. Synthetic biology has a strong barrier attribute because of its multi-disciplinary intersection, high requirements for technology, cost control and R & D personnel.
According to McKinsey research, bio-manufactured products can cover 60% of chemically manufactured products, and future bio-manufacturing methods are expected to have a great impact on traditional industries such as medicine, chemical industry, food, energy, materials and agriculture in the future.
Greenhouse gas emission reduction, technological progress, cost reduction, policy support, capital inflows and other factors promote the rapid development of the industry.
In the case of rising global temperatures and the urgent demand for new modes of production, synthetic biological manufacturing is expected to become the optimal solution. With the progress of the underlying technology and the reduction of costs, synthetic biology has made considerable progress. At the same time, the encouragement of the government policy to the industry is self-evident. Under the promotion of capital, the synthetic biology industry has ushered in the opportunity of rapid development.
According to McKinsey's analysis, the annual economic impact of synthetic biology is expected to reach US $1.8 to US $3.6 trillion in 2030-2040 and US $100 billion by 2025. According to CB Insights's forecast, the global market for synthetic biology will be about $5.3 billion in 2019, will expand to about $18.9 billion by 2024, and will be 28.8 per cent of CAGR in 2019-2024.
Risk Tips:Product R & D risk, technology development risk less than expected, market competition aggravating risk, raw material cost rising risk, policy risk, geopolitical risk.